Conversion from mycophenolate mofetil to delayed formulation in pediatric renal transplantation: Higher mycophenolic acid predose level but no changes in the immune biomarkers

Pediatric Transplantation

Volumn 13, Issue 6, 2009, Pages 731-736

  Ferraris, Jorge R ^a,e   Tambutti, Mónica L ^b   Prigoshin, Norma ^b   Grosman, Mauricio ^c   Cardoni, Rita L ^d  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^c Laboratorio de Bioquímica Médica   (Argentina)

^d Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^e NONE   (Argentina)

Author keywords

Children; Cytokine; Enteric coated mycophenolate sodium; Kidney transplantation; Mycophenolate mofetil

Indexed keywords

CREATININE; GAMMA INTERFERON; HEMOGLOBIN; INTERLEUKIN 10; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOKINE RELEASE; DRUG EFFECT; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY TRANSPLANTATION; MALE; PRESCHOOL CHILD; PROTEIN URINE LEVEL; SCHOOL CHILD;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CREATININE; CYTOKINES; DELAYED-ACTION PREPARATIONS; FEMALE; HEMOGLOBINS; HUMANS; IMMUNE SYSTEM; INTERFERON-GAMMA; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68849130192     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2009.01194.x     Document Type: Article

References (30)

1. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC. RS-61443 - a new, potent immunosuppressive agent. Transplantation 1991 : 51 : 27 31.
2. Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991 : 33 : 161 173.
3. Ferraris JR, Ghezzi LF, Vallejo G, Piantanida JJ, Araujo JL, Sojo ET. Improved long-term allograft function in pediatric renal transplantation with mycophenolate mofetil. Pediatr Transplant 2005 : 9 : 178 182.
4. Ferraris JR, Tambutti ML, Redal MA, Bustos D, Ramirez JA, Prigoshin N. Conversion from azathioprine to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection. Transplantation 2000 : 70 : 297 301.
5. Ferraris JR, Duca P, Prigoshin N, et al. Mycophenolate mofetil and reduced doses of cyclosporine in pediatric liver transplantation with chronic renal dysfunction: Changes in the immune responses. Pediatr Transplant 2004 : 8 : 454 459.
6. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002 : 13 : 759 768.
7. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006 : 82 : 102 107.
8. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004 : 4 : 231 236.
9. Kaplan B, Meier-Kriesche HU, Minnick P, et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant 2005 : 19 : 551 558.
10. Bohler T, Canivet C, Galvani S, et al. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients. Int Immunopharmacol 2008 : 8 : 769 773.
11. Sato K, Anada N, Sato T, et al. Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients. Clin Transplant 2004 : 18 : 585 590.
12. Hocker B, Weber LT, Bunchman T, Rashford M, Tonshoff B. Mycophenolate mofetil suspension in pediatric renal transplantation: Three-year data from the tricontinental trial. Pediatr Transplant 2005 : 9 : 504 511.
13. Butani L, Palmer J, Baluarte HJ, Polinsky MS. Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection. Transplantation 1999 : 68 : 83 86.
14. Bjarnason I. Enteric coating of mycophenolate sodium: A rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transplant Proc 2001 : 33 : 3238 3240.
15. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004 : 4 : 237 243.
16. Budde K, Knoll G, Curtis J, et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol 2006 : 66 : 103 111. (Pubitemid 44219436)
17. Salvadori M, Holzer H, Civati G, et al. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients. Clin Nephrol 2006 : 66 : 112 119.
18. Massari P, Duro-Garcia V, Giron F, et al. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc 2005 : 37 : 916 919.
19. Pape L, Ahlenstiel T, Kreuzer M, Ehrich JH. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children. Pediatr Transplant 2008 : 12 : 640 642.
20. Filler G. Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation. Pediatr Transplant 2006 : 10 : 707 711.
21. Mourad M, Malaise J, Chaib Eddour D, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 2001 : 47 : 1241 1248.
22. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996 : 61 : 1029 1037.
23. van Besouw NM, van der Mast BJ, Smak Gregoor PJ, et al. Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrol Dial Transplant 1999 : 14 : 2710 2713.
24. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: Characterization and relation to pharmacodynamics. Clin Chem 1995 : 41 : 1011 1017.
25. Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 1996 : 62 : 666 672.
26. Ferraris JR, Tambutti ML, Cardoni RL, Prigoshin N. Conversion from cyclosporine A to tacrolimus in pediatric kidney transplant recipients with chronic rejection: Changes in the immune responses. Transplantation 2004 : 77 : 532 537.
27. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin 10. Annu Rev Immunol 1993 : 11 : 165 190.
28. Tary-Lehmann M, Hricik DE, Justice AC, Potter NS, Heeger PS. Enzyme-linked immunosorbent assay spot detection of interferon-gamma and interleukin 5-producing cells as a predictive marker for renal allograft failure. Transplantation 1998 : 66 : 219 224.
29. Zuo XJ, Jordan SC, Wilkinson A, et al. Interleukin-12 mRNA levels in renal allograft fine-needle aspirates do not correlate with acute transplant rejection. Transplantation 1995 : 60 : 1360 1362.
30. Chandraker A, Azuma H, Nadeau K, et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998 : 101 : 2309 2318.